Pasithea Therapeutics Corp (NASDAQ: KTTA) shares are trading sharply higher Wednesday following a string of upbeat updates.
The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in ...
Researchers have found in a new study that COVID-19 infection is associated with significantly elevated blood concentrations ...
Celltrion, Inc. today announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg) ...
Verywell Health on MSN
5 Things You Didn't Know About Turmeric
Turmeric can support your health, but taking too much—or at the wrong time—may cause unwanted effects. Learn what to know ...
“The monoclonal antibodies rituximab, ocrelizumab, ofatumumab (Kesimpta), and ublituximab (Briumvi) provide outstanding ...
The North America Mass Spectrometry Market is poised to surge from US$ 2.6 Billion in 2024 to US$ 4.87 Billion by 2033, ...
The FDA granted fast track designation to AVZO-103 for the treatment of patients with previously treated locally advanced or metastatic urothelial cancer.
Celltrion, Inc. today announced that Health Canada has approved Eydenzelt (R) , a biosimilar referencing Eylea (R) (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all ...
Clearmind Medicine rose 7.09% in pre-market trading after announcing enrollment of first patient in trial for alcohol use ...
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated, “The recruitment of the first patient at TASMC is a significant step that further accelerates our global trial. We are grateful to Prof.
SoluScience, a leader in the field of drug solubility, had been working to solve that problem, but it has now filed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback